Latest Releases

20 October 2011  Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics

Ipsen (Euronext: IPN, ADR: IPSEY) and Syntaxin, a biotechnology company specialising in innovative biopharmaceutical therapies targeting cell secretion pathways, announced today a global strategic col...

View

14 June 2011  Syntaxin and University School of Medicine, Geneva were awarded the Presidential Poster Prize at ENDO 2011, the Endocrine Society’s 13th Annual meeting held in Boston Mass 4-7th June 2011

...

View

11 May 2011  Syntaxin enters manufacturing agreement with SynCo Bio Partners B.V

Oxford, UK, 11th May 2011: Syntaxin, a biotechnology company specialising in innovative biopharmaceutical therapies for cell secretion control, is pleased to announce a manufacturing agreement with Sy...

View

02 March 2011  Syntaxin announces its partner Allergan enters Phase II trials with Re‐Targeted Endopeptidase Drug

Oxford, UK, 2nd March 2011: Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announces its partner Allergan Inc has initiated two Phase II trials...

View

07 January 2011  Russell G. Greig Appointed as Chairman

Oxford, UK, 6th January 2011: Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announced Dr Russell G. Greig, Ph. D., has been appointed as Chairm...

View